Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0A9BZ
|
||||
Former ID |
DNC006739
|
||||
Drug Name |
PSB-601
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [530243] | ||
Structure |
Download2D MOL |
||||
Formula |
C25H28N6O4S
|
||||
Canonical SMILES |
CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=C(C=C3)S(=O)(=O)N4CCN<br />(CC4)CC5=CC=CC=C5
|
||||
InChI |
1S/C25H28N6O4S/c1-2-12-31-24(32)21-23(28-25(31)33)27-22(26-21)19-8-10-20(11-9-19)36(34,35)30-15-13-29(14-16-30)17-18-6-4-3-5-7-18/h3-11H,2,12-17H2,1H3,(H,26,27)(H,28,33)
|
||||
InChIKey |
HHNGYTVWOXXKET-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [530243] | |
Adenosine A2b receptor | Target Info | Inhibitor | [530966] | ||
Adenosine A2a receptor | Target Info | Inhibitor | [530243] | ||
KEGG Pathway | cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | |||||
Sphingolipid signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Morphine addictionhsa04015:Rap1 signaling pathway | |||||
Calcium signaling pathway | |||||
Vascular smooth muscle contraction | |||||
Alcoholismhsa04015:Rap1 signaling pathway | |||||
Parkinson's disease | |||||
Alcoholism | |||||
Pathway Interaction Database | C-MYB transcription factor networkhif2pathway:HIF-2-alpha transcription factor network | ||||
References | |||||
Ref 530243 | J Med Chem. 2009 Jul 9;52(13):3994-4006.1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. | ||||
Ref 530966 | Eur J Med Chem. 2010 Aug;45(8):3459-71. Epub 2010 May 7.Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.